Мультисистемная атрофия: обзор актуальных результатов клинических исследований новых препаратов (часть 2)

Мультисистемная атрофия (МСА) представляет собой редкое нейродегенеративное заболевание с прогрессирующим течением, возникающее спорадически. Для МСА характерно сочетание вегетативных расстройств и двигательных нарушений, включая паркинсонический синдром, мозжечковую атаксию, пирамидные симптомы и другие проявления. Диагностика этого заболевания часто затруднена из-за разнообразия клинических проявлений и недостаточной информированности неврологов о данном заболевании, что приводит к ошибочным диагнозам или наблюдению пациентов у специалистов других направлений. В зависимости от преобладающих симптомов и локализации поражения в центральной нервной системе выделяют два клинических варианта МСА: паркинсонический (МСА-П, MSA-P) и мозжечковый (МСА-М, MSA-C). В данной статье представлены важные текущие доклинические и клинические исследования, сосредоточенные на замедлении прогрессирования МСА: препараты, нацеленные на патологический α-синуклеин, нейропротективные и противовоспалительные методы. Также представлены актуальные данные исследований препаратов, нацеленных на симптоматическое лечение МСА..

1. Garg D, Srivastava AK, Jaryal AK, Rajan R, Singh A, Pandit AK, Vibha D, Shukla G, Garg A, Pandey RM, Prasad K. Is There a Difference in Autonomic Dysfunction Between Multiple System Atrophy Subtypes? Mov Disord Clin Pract. 2020 Apr 9; 7 (4): 405–412. DOI: 10.1002/mdc3.12936. PMID: 32373657; PMCID: PMC7197320.

2. Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics. J. Biol Chem. 2019 Jan 18; 294 (3): 1045–1058. DOI: 10.1074/jbc.RA118.004471. Epub 2018 Nov 26. PMID: 30478174; PMCID: PMC6341389.

3. Bendetowicz D, Fabbri M, Sirna F, Fernagut PO, Foubert-Samier A, Saulnier T, Le Traon AP, Proust-Lima C, Rascol O, Meissner WG. Recent Advances in Clinical Trials in Multiple System Atrophy. Curr Neurol Neurosci Rep. 2024 Apr; 24 (4): 95–112. DOI: 10.1007/s11910-024-01335-0. Epub 2024 Feb 28. PMID: 38416311.

4. Heras-Garvin A, Stefanova N. MSA: From basic mechanisms to experimental therapeutics. Parkinsonism Relat Disord. 2020 Apr; 73: 94–104. DOI: 10.1016/j.parkreldis.2020.01.010. Epub 2020 Jan 23. PMID: 32005598.

5. Liu M, Wang Z, Shang H. Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. J. Neurol. 2024 May; 271 (5): 2324–2344.DOI: 10.1007/s00415-024-12269-5. Epub 2024 Mar 14. PMID: 38483626; PMCID: PMC11055738.

6. Sidoroff V, Bower P, Stefanova N, Fanciulli A, Stankovic I, Poewe W, Seppi K, Wenning GK, Krismer F. Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022? J. Parkinsons Dis. 2022; 12 (5): 1369–1387. DOI: 10.3233/JPD-223183. PMID: 35491799; PMCID: PMC9398078.

7. Wan L, Zhu S, Chen Z, Qiu R, Tang B, Jiang H. Multidimensional biomarkers for multiple system atrophy: an update and future directions. Transl Neurodegener. 2023 Jul 28; 12 (1): 38.DOI: 10.1186/s40035-023-00370-0. PMID: 37501056; PMCID: PMC10375766.

8. Henriquez G, Narayan M. Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease. Explor Neuroprot Ther. 2023; 3: 207–34. https://doi.org/10.37349/ent.2023.00048

9. Mészáros, L., Riemenschneider, M.J., Gassner, H. et al. Human alpha-synuclein overexpressing MBP29 mice mimic functional and structural hallmarks of the cerebellar subtype of multiple system atrophy. Acta neuropathol commun. 9, 682021; 9: 68. https://doi.org/10.1186/s40478-021-01166-x

10. Mandler M, Valera E, Rockenstein E, Mante M. et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015 Mar 19; 10: 10. DOI: 10.1186/s13024-015-0008-9. PMID: 25886309; PMCID: PMC4411775.

11. Volc D, Poewe W, Kutzelnigg A, Lührs P. et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020 Jul; 19 (7): 591–600. DOI: 10.1016/S1474–4422(20)30136-8. PMID: 32562684.

12. Meissner WG, Traon AP, Foubert-Samier A, Galabova G. et al. AFF009 Study Investigators. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord. 2020 Nov; 35 (11): 1957–1965. DOI: 10.1002/mds.28218. Epub 2020 Sep 3. PMID: 32882100; PMCID: PMC7754431.

13. Schenk DB, Koller M, Ness DK, Griffith SG. et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017 Feb; 32 (2): 211–218. DOI: 10.1002/mds.26878. Epub 2016 Nov 25. PMID: 27886407; PMCID: PMC5324684.

14. Jankovic J, Goodman I, Safirstein B, Marmon TK, et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1; 75 (10): 1206–1214. DOI: 10.1001/jamaneurol.2018.1487. PMID: 29913017; PMCID: PMC6233845.

15. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct; 19 (10): 673–694. DOI: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

16. Igarashi J., Niwa Y., & Sugiyama D. (2022). Research and development of oligonucleotide therapeutics in Japan for rare diseases. Future Rare Diseases. 2 (1), FRD19. https://doi.org/10.2217/frd-2021-0008

17. Cole TA, Zhao H, Collier TJ, Sandoval I. et al. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. JCI Insight. 2021 Mar 8; 6 (5): e135633. DOI: 10.1172/jci.insight.135633. PMID: 33682798; PMCID: PMC8021121.

18. Morato Torres CA, Wassouf Z, Zafar F, Sastre D, Outeiro TF, Schüle B. The Role of Alpha-Synuclein and Other Parkinson's Genes in Neurodevelopmental and Neurodegenerative Disorders. Int J. Mol Sci. 2020 Aug 10; 21 (16): 5724. DOI: 10.3390/ijms21165724. PMID: 32785033; PMCID: PMC7460874.

19. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D. et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000 Jan; 25 (1): 239–52. DOI: 10.1016/s0896-6273(00)80886-7. PMID: 10707987.

20. Ninkina N, Tarasova TV, Chaprov KD, Roman AY. et al. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice. Neurobiol Aging. 2020 Jul; 91: 76–87. DOI: 10.1016/j.neurobiolaging.2020.02.026. Epub 2020 Mar 5. PMID: 32224067; PMCID: PMC7242904.

21. Wagner J, Ryazanov S, Leonov A, Levin J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun; 125 (6): 795–813. DOI: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19. PMID: 23604588; PMCID: PMC3661926.

22. Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A. et al. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019 Feb; 34 (2): 255–263. DOI: 10.1002/mds.27562. Epub 2018 Nov 19. PMID: 30452793; PMCID: PMC6492169.

23. Lemos M, Venezia S, Refolo V, Heras-Garvin A. et al. Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegener. 2020 Sep 24; 9 (1): 38. DOI: 10.1186/s40035-020-00217-y. PMID: 32972456; PMCID: PMC7513530.

24. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991 Aug; 114 (Pt 4): 1953–75. DOI: 10.1093/brain/114.4.1953. PMID: 1832073.

25. Kaindlstorfer C, Jellinger KA, Eschlböck S, Stefanova N, Weiss G, Wenning GK. The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. J. Alzheimers Dis. 2018; 61 (4): 1253–1273.DOI: 10.3233/JAD-170601. PMID: 29376857; PMCID: PMC5798525.

26. Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012 Jun 20; 23 (9): 576–80. DOI: 10.1097/WNR.0b013e328354a1f0. PMID: 22581044.

27. Follmer C, Coelho-Cerqueira E, Yatabe-Franco DY, Araujo GD, Pinheiro AS, Domont GB, Eliezer D. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). J. Biol Chem. 2015 Nov 13; 290 (46): 27660–79. DOI: 10.1074/jbc.M115.686584. Epub 2015 Sep 17. PMID: 26381411; PMCID: PMC4646016.

28. Finkelstein DI, Billings JL, Adlard PA, Ayton S. et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2021 Sep 29; 9 (1): 161. DOI: 10.1186/s40478-021-01258-8. PMID: 28659169; PMCID: PMC5490188.

29. Finkelstein DI, Shukla JJ, Cherny RA, Billings JL, Saleh E, Stefanova N, Barnham KJ, Adlard PA. The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy. J. Parkinsons Dis. 2022; 12 (1): 105–115. DOI: 10.3233/JPD-212877. PMID: 34744051; PMCID: PMC9028676.

30. Stamler D., Bradbury M., Wong C., Offman E. A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation (S4.001). Neurology. 2019; 92 (Suppl. 15): S4.001. https://doi.org/10.1212/WNL.92.15_supplement.S4.001

31. Herrera-Vaquero M, Bouquio D, Kallab M, Biggs K. et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. Biochim Biophys Acta Mol Basis Dis. 2019 Nov 1; 1865 (11): 165513. DOI: 10.1016/j.bbadis.2019.07.007. Epub 2019 Jul 16. PMID: 31319154; PMCID: PMC8425273.

32. Bengoa-Vergniory N, Faggiani E, Ramos-Gonzalez P, Kirkiz E. et al. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. Nat Commun. 2020 Sep 28; 11 (1): 4885. DOI: 10.1038/s41467-020-18689-x. PMID: 32985503; PMCID: PMC7522721.

33. Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci USA. 2016 Aug 23; 113 (34): 9593–8. DOI: 10.1073/pnas.1609291113. Epub 2016 Aug 1. PMID: 27482103; PMCID: PMC5003293.

34. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, Heinecke JW. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 2004 Aug;90(3):724–33. DOI: 10.1111/j.1471-4159.2004.02527.x. PMID: 15255951.

35. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 2005 Jul 13; 25 (28): 6594–600. DOI: 10.1523/JNEUROSCI.0970-05.2005. PMID: 16014720; PMCID: PMC6725426.

36. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 2008 Jan; 18 (1): 86–95. DOI: 10.1111/j.1750–3639.2007.00110.x. Epub 2007 Nov 27. PMID: 18042261; PMCID: PMC8095620.

37. Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res. 2012 May; 21 (4): 393–404. DOI: 10.1007/s12640-011-9294-3. Epub 2011 Dec 8. PMID: 22161470.

38. Jucaite A, Svenningsson P, Rinne JO, Cselényi Z. et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep; 138 (Pt 9): 2687–700. DOI: 10.1093/brain/awv184. Epub 2015 Jul 1. PMID: 26137956.

39. Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl. J. Med. 2013 Jul 18; 369 (3): 233–44. DOI: 10.1056/NEJMoa1212115. Epub 2013 Jun 12. Erratum in: N Engl J Med. 2014 Jul 3; 371 (1): 94. PMID: 23758206.

40. Monzio Compagnoni G, Kleiner G, Samarani M, Aureli M. et al. Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. Stem Cell Reports. 2018 Nov 13; 11 (5): 1185–1198. DOI: 10.1016/j.stemcr.2018.09.007. Epub 2018 Oct 18. PMID: 30344007; PMCID: PMC6234905.

41. Nakamoto FK, Okamoto S, Mitsui J, Sone T. et al. The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. Sci Rep. 2018 Sep 21; 8 (1): 14215. DOI: 10.1038/s41598-018-32573-1. PMID: 30242188; PMCID: PMC6155102.

42. Mitsui J, Matsukawa T, Uemura Y, Kawahara T. et al. High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. E Clinical Medicine. 2023 Apr 14; 59: 101920. DOI: 10.1016/j.eclinm.2023.101920. PMID: 37256098; PMCID: PMC10225719.

43. Mitsui J, Matsukawa T, Tanaka M, Saito-Sato. et al.(2022). Randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults. Neurology and Clinical Neuroscience. 10 (1) 14-24. DOI: 10.1111/ncn3.12566

44. Krismer F, Seppi K, Wenning GK, Abler V, Papapetropoulos S, Poewe W. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Mov Disord. 2016 Oct; 31 (10): 1577–1581. DOI: 10.1002/mds.26743. PMID: 27474888

45. Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain. 2017 May 1; 140 (5): 1420–1436. DOI: 10.1093/brain/awx044. PMID: 28334990; PMCID: PMC6248513.

46. Sanchez-Perez A, Llansola M, Cauli O, Felipo V. Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function. Cerebellum. 2005; 4 (3): 162–70. DOI: 10.1080/14734220510008003. PMID: 16147948.

47. Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy. Available online: https://clinicaltrials.gov/ct2/show/NCT03901638

48. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am.J. Med. 1993 Jul; 95 (1): 38–48. DOI: 10.1016/00029343(93)90230-m. PMID: 7687093.

49. Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure. Available online: https://clinicaltrials.gov/ct2/show/NCT02897063

50. Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J. Neurosci Res. 2000 Jul 15; 61 (2): 121–7. DOI: 10.1002/1097-4547(20000715)61:23.0.CO;2-4. PMID: 10878583.

51. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE). Available online: https://clinicaltrials.gov/ct2/show/NCT02586623

52. Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014 Dec; 64 (6): 1235–40. DOI: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2. PMID: 25185131; PMCID: PMC4231172.

53. Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. Hypertension. 2019 Jan; 73 (1): 235–241. DOI: 10.1161/HYPERTENSIONAHA.118.11790. PMID: 30571543; PMCID: PMC6309809.

54. Norepinephrine Transporter Blockade, Autonomic Failure. Available online: https://clinicaltrials.gov/ct2/show/NCT02796209

55. Safinamide for Multiple System Atrophy (MSA). Available online: https://clinicaltrials.gov/ct2/show/NCT03753763